Expression of ergotope-associated markers of T lymphocytes in atopic dermatitis after in vitro polyclonal activation


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

The antiergotypic response leads to the formation of effector T cells able to eliminate activated lymphocytes independently of their antigenic specificity, since the targets of these cells are molecules produced during cell activation (ergotopes). In this paper, we describe the level of expression of the ergotope-associated markers CD25, HSP60, and HLA-DR by the T lymphocytes isolated from the blood of atopic dermatitis patients immediately after isolation and after cultivation. After 10-day cultivation in the presence of anti-CD3 antibodies and IL-2, the expression levels of early and late activation markers in T cells have changed: the shares of CD25-positive CD4+ and CD8+ lymphocytes increase to 68 and 47%, respectively, and the share of HLA-DR-positive cells increases to 26 and 33%. The density of HLA-DR molecules on the surface of activated T cells increases more than fivefold. Almost all T cells before and after cultivation express 60 kDa heatshock protein (HSP60); however, the CD4+ cells activated in vitro contain more HSP60 molecules than do the in vitro-activated CD8+ cells and the CD4+ cells of peripheral blood. Thus, the T cells of atopic-dermatitis patients have the status of activated cells because they express sufficient amounts of early and late activation markers; presumably, they can enhance the induction of antiergotypic response when administered to patients. Taking into account that antiergotypic regulation acts on activated T cells independently of their antigenic specificity, immunotherapy utilizing autologous activated T lymphocytes can be of interest as a method for targeted action on pathogenetic components of atopic dermatitis.

Об авторах

E. Blinova

Institute of Fundamental and Clinical Immunology

Автор, ответственный за переписку.
Email: blinovaelena-85@yandex.ru
Россия, Novosibirsk, 630099

E. Pashkina

Institute of Fundamental and Clinical Immunology

Email: blinovaelena-85@yandex.ru
Россия, Novosibirsk, 630099

A. Tevs

Clinic of Immunopathology; Chair of Clinical Immunology

Email: blinovaelena-85@yandex.ru
Россия, Novosibirsk, 630047; Novosibirsk, 630047

V. Nepomnyashchikh

Clinic of Immunopathology

Email: blinovaelena-85@yandex.ru
Россия, Novosibirsk, 630047

M. Leonova

Clinic of Immunopathology

Email: blinovaelena-85@yandex.ru
Россия, Novosibirsk, 630047

D. Demina

Clinic of Immunopathology

Email: blinovaelena-85@yandex.ru
Россия, Novosibirsk, 630047

V. Kozlov

Institute of Fundamental and Clinical Immunology; Chair of Clinical Immunology

Email: blinovaelena-85@yandex.ru
Россия, Novosibirsk, 630099; Novosibirsk, 630047

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML

© Pleiades Publishing, Ltd., 2017

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).